John Potomski, DO
Geriatric Medicine · Melbourne, FLNPI 1083657183
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 50.6% of the total. Reporting peaked in 2023 at $10,964 and has fallen 67.2% since, to $3,592 in 2025. Among geriatric medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 360 payments — averaging $85.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$16K
- Acadia Pharmaceuticals Inc$4K
- Teva Pharmaceuticals USA, Inc.$3K
- Corium, LLC$2K
- Sunovion Pharmaceuticals Inc.$643
- Johnson & Johnson$613
- plus $5K from 24 others
What the payments were for
- Consulting fees$16,94855%
- Travel & lodging$4,65715%
- Food & beverage$9,17030%
- Education$1751%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 52 | $15,676 |
| Acadia Pharmaceuticals Inc | 47 | $3,944 |
| Teva Pharmaceuticals USA, Inc. | 72 | $3,282 |
| Corium, LLC | 8 | $2,193 |
| Sunovion Pharmaceuticals Inc. | 36 | $643 |
| Johnson & Johnson | 19 | $613 |
| Smith+Nephew | 1 | $602 |
| Novartis | 22 | $557 |
| Vanda Pharmaceuticals Inc. | 4 | $500 |
| Otsuka America Pharmaceutical, Inc. | 7 | $396 |
| Sun Pharmaceutical Industries Inc. | 17 | $354 |
| Astellas Pharma US Inc | 8 | $349 |
| Avanir Pharmaceuticals, Inc. | 17 | $310 |
| Sumitomo Pharma America, Inc. | 9 | $272 |
| Lilly USA, LLC | 7 | $249 |
| UCB, Inc. | 8 | $241 |
| Mylan Specialty L.p. | 4 | $200 |
| Cvrx, Inc. | 1 | $106 |
| AstraZeneca | 3 | $84 |
| Neurelis, Inc. | 4 | $63 |
| SK Life Science, Inc. | 2 | $54 |
| Ardelyx, Inc. | 2 | $53 |
| Amgen | 1 | $48 |
| Scilex Pharmaceuticals Inc. | 2 | $34 |
| Urovant Sciences Inc | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $31 |
| Indivior Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$14,507
- NUPLAZID$2,837
- Austedo XR$2,351
- Azstarys$2,001
- Fanapt$500
- XARELTO$225
- ENTRESTO$222
- REXULTI$222
- ADLARITY$147
- Yupelri$125
- MYRBETRIQ$125
- GEMTESA$125
- APTIOM$121
- KAPSPARGO$112
- DRIZALMA SPRINKLE$112
- EZALLOR SPRINKLE$112
- Barostim Neo System$106
How this compares
$30,950 in reported general payments places this provider in the 95th percentile of 305 geriatric medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,942 | $582,097 |
| NuplazidPimavanserin Tartrate | 77 | $213,185 |
| EntrestoSacubitril/Valsartan | 614 | $212,691 |
| XareltoRivaroxaban | 668 | $195,682 |
| LinzessLinaclotide | 267 | $154,594 |
| AptiomEslicarbazepine Acetate | 215 | $140,719 |
| ErtapenemErtapenem Sodium | 260 | $101,909 |
| TrulicityDulaglutide | 143 | $91,132 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 134 | $79,818 |
| IngrezzaValbenazine Tosylate | 14 | $76,775 |
| JardianceEmpagliflozin | 229 | $71,263 |
| MyrbetriqMirabegron | 291 | $70,908 |
| XifaxanRifaximin | 44 | $65,651 |
| Divalproex Sodium | 694 | $57,469 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 433 | $55,182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto, Invega Sustenna, Procrit | $613 | $268,588729 claims |
| Acadia Pharmaceuticals IncNuplazid | $3,944 | $213,18577 claims |
| NovartisEntresto | $557 | $212,691614 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $643 | $140,719215 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $249 | $116,378184 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $15,676 | $76,77514 claims |
| Astellas Pharma US IncMyrbetriq | $349 | $70,908291 claims |
| Smith+NephewSantyl | $602 | $54,21561 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $310 | $32,95137 claims |
| MerckJanuvia | $14 | $30,225104 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $3,282 | $29,46217 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $272 | $27,886107 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 305 geriatric medicine providers in Florida.
Other geriatric medicine in Melbourne
- Sarunas SkirkMelbourne$4K
- Malcolm FraserBrooksville$359K
- Andrew ScanameoTallahassee$172K
- Naushira PandyaDavie$145K
- Rosemary LairdViera$64K
- Jonathan AppelbaumMonticello$59K
- Valeria Baldivieso HurtadoWinter Park$28K
- Kae FerberNaples$18K
- Stuti DangMiami$17K
- Angel HerreraNaples$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.